编号：2021-004 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|----------------------------------|-----------------------------------------------------|-------|------------------| | | | | | | | | | □√特定对象调研 □分析师会议 | | | | 投资者关系活 | □媒体采访 | □业绩说明会 | | | | 动类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 | | | | | | | 贵州金控集团贵州省贵鑫瑞和创业投资管理有限责任公司 | | 李德祥、宋邱宇良 | | | 贵阳市贵山基金管理有限公司 | 陈焕斌 | | 闫昱辰 | | | | 深圳市深商控股集团深圳市深商玖柒陆农牧有限公司 叶悦 | | 赖俊驹 | | | 华创证券有 ...

编号：2021-003 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------| | | □√特定对象调研 □分析师会议 | | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | | | | | 参与单位名称 及人员姓名 | 华金证券 魏赟 | | | 时间 | 2021 年 12 月 2 日 | | | | ...

编号：2022-003 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------------|----------------|------------------------|------------------------------------------------------------------------| | 投资者关系活 \n动类别 \n | □√特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 \n□现场参观 \n□√其他（线上会议） | | □路演活动 | | | | 德邦证券 陈进 开源证券 | | | 蔡明子、余汝意、吴瑕 | | | 海富通基金 高通、宫衍海 | | 华 ...

编号：2022-001 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | --- | |--------------|--------------|------------------------------|-----------------|--------|---------------------------------------|-------| | | | | | | | | | | | □√特定对象调研 □√分析师会议 | | | | | | 投资者关系活 | | □媒体采访 □业绩说明会 | | | | | | 动类别 | □新闻发布会 | | □路演活动 | | | | | | □现场参观 | | | | | | | | | □√其他（电话会议、线上会议） | | | | | | | 华安证券 | | | | 谭国超、李昌幸、沈毅、朱晓珊 德邦证券 | 陈进 | | | 富国基金 | 于洋、张富盛 | 博时基金 | | 孔令熙 | ...

编号：2022-004 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |----------------------------|-------------------------|-------------------------------------------------------------|----------------------------------------------------|----------|----------------------------------------------------------------------| | 投资者关系活 \n动类别 \n | □新闻发布会 \n□现场参观 | □√特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n | □路演活动 | | | | | □其他 | | | | | | | 易方达基金 | | 杨桢霄 长城基金 | | 唐项涛 | | | ...

编号：2022-006 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |----------------------------|---------------------------------|----------------|-----------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------| | 投资者关系活 \n动类别 \n | □新闻发布会 \n□现场参观 \n□其他 | | □√特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□路演活动 | | | | | 国盛证券 | 杨春雨、缪牧一 | | | | | ...

编号：2022-005 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------------------------|---------------------------------|--------------------------------------------------------|--------------------------------------------------|------------------------------------------------------------------------| | 投资者关系活 \n动类别 \n | □新闻发布会 \n□现场参观 \n□其他 | □√特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n | □路演活动 | | | | 万家基金 | 况晓 | 嘉实基金 | 李慧 | | 参与单位名称 | | | 恒越基金 张其美 华泰证券 | 刘诗瑶 | ...

编号：2022-002 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|----------------------------------|----------------|--------------------------------------------|-------------------------------------------------------| | | | | | | | | | | □√特定对象调研 □√分析师会议 | | | 投资者关系活 | | | □媒体采访 □业绩说明会 | | | 动类别 | □新闻发布会 | | □路演活动 | | | | □现场参观 | | | | | | □√其他（线上会议） | | | | | | | | 华金证券 魏赟 海通证券 郑琴、王郑洋 | | | | 东兴证券 | 胡博新 | | 德邦证券 陈铁林、陈进 | | | | | 广发证券 罗佳荣 汇添富基金 ...

编号：2022-013 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Product Overview - The company has 26 products listed in the National Medical Insurance Directory, 10 in the National Essential Medicines List, 21 OTC products, and 13 exclusive products [2] - Key products include Kuntai Capsule, Kushi Gel, Ningpitai Capsule, and Xia Ku Cao Oral Liquid, with Kuntai Capsule being a patented product and the only traditional Chinese medicine for improving ovarian function [2][3] Growth Strategies - The company focuses on modern traditional Chinese medicine, targeting women's health, urinary system health, and chronic diseases, while also covering elderly and pediatric medications [3] - Plans to enhance the OTC market presence and implement an integrated online and offline marketing strategy [3] - Aims to establish a cluster of patented traditional Chinese medicine products and become a leading brand in specific therapeutic areas within 2-3 years [3] Research and Development - The company has established three R&D bases and is working on new drug innovations, including three products that have completed Phase III clinical trials [5][6] - Ongoing research includes classic traditional Chinese medicine formulas and clinical studies for key products [5][6] Market Position - The company ranks highly in the gynecology and urinary system sectors, with Kuntai Capsule ranked second in 2018 and recognized in various clinical value rankings [4][5] - OTC sales account for approximately 30% of total revenue [5] Financial Performance - The sales expense ratio for 2021 was 48.65%, focusing on professional academic promotion and OTC brand promotion [5] Future Plans - The company plans to accelerate the application for market approval for new drugs expected to be submitted before 2023 [6] - It is also exploring potential mergers and acquisitions to enhance its market position [6] Brand Development - The "Heyan" brand for women's health management is being promoted in four provinces, with advertising campaigns launched in various media [7][8]